Martina Huemer1,2,3, Daniel R Carvalho4, Jaime M Brum5, Özlem Ünal6,7, Turgay Coskun6, James D Weisfeld-Adams8,9, Nina L Schrager8, Sabine Scholl-Bürgi10, Andrea Schlune11, Markus G Donner12, Martin Hersberger13, Claudio Gemperle13, Brunhilde Riesner14, Hanno Ulmer15, Johannes Häberle16,17, Daniela Karall10. 1. Division of Metabolic Diseases and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. martina.huemer@lkhb.at. 2. Radiz - Rare Disease Initiative Zurich, University Zurich, Zurich, Switzerland. martina.huemer@lkhb.at. 3. Department of Paediatrics, Landeskrankenhaus Bregenz, Bregenz, Austria. martina.huemer@lkhb.at. 4. Genetic Unit, SARAH Network of Rehabilitation Hospital, Brasilia, Brazil. 5. Molecular Pathology Department, Rede Sarah de Hospitais de Reabilitação, Brasilia, Brazil. 6. Department of Paediatrics, Division of Paediatric Nutrition and Metabolism, Hacettepe University Faculty of Medicine, Ankara, Turkey. 7. Ankara Children's Hospital, Haematology-Oncology Research and Education Hospital, Ankara, Turkey. 8. Program for Inherited Metabolic Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 9. Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. 10. Clinic for Pediatrics I, Inherited Metabolic Disorders, Medical University of Innsbruck, Innsbruck, Austria. 11. Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, Düsseldorf, Germany. 12. Department of Gastroenterology, Hepatology and Infectious diseases, Heinrich Heine University, Düsseldorf, Germany. 13. Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Zurich, Switzerland. 14. Department of Paediatrics, Landeskrankenhaus Bregenz, Bregenz, Austria. 15. Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria. 16. Division of Metabolic Diseases and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. 17. Radiz - Rare Disease Initiative Zurich, University Zurich, Zurich, Switzerland.
Abstract
BACKGROUND: Arginase 1 (ARG1) deficiency is a rare urea cycle disorder (UCD). This hypothesis-generating study explored clinical phenotypes, metabolic profiles, molecular genetics, and treatment approaches in a cohort of children and adults with ARG1 deficiency to add to our understanding of the underlying pathophysiology. METHODS: Clinical data were retrieved retrospectively from physicians using a questionnaire survey. Plasma aminoacids, guanidinoacetate (GAA), parameters indicating oxidative stress and nitric oxide (NO) synthesis as well as asymmetric dimethylarginine (ADMA) were measured at a single study site. RESULTS: Nineteen individuals with ARG1 deficiency and 19 matched controls were included in the study. In patients, paraparesis, cognitive impairment, and seizures were significantly associated suggesting a shared underlying pathophysiology. In patients plasma GAA exceeded normal ranges and plasma ADMA was significantly elevated. Compared to controls, nitrate was significantly higher, and the nitrite:nitrate ratio significantly lower in subjects with ARG1 deficiency suggesting an advantage for NO synthesis by inducible NO synthase (iNOS) over endothelial NOS (eNOS). Logistic regression revealed no significant impact of any of the biochemical parameters (including arginine, nitrates, ADMA, GAA, oxidative stress) or protein restriction on long-term outcome. CONCLUSION: Three main hypotheses which must be evaluated in a hypothesis driven confirmatory study are delineated from this study: 1) clinical manifestations in ARG1 deficiency are not correlated with arginine, protein intake, ADMA, nitrates or oxidative stress. 2) GAA is elevated and may be a marker or an active part of the pathophysiology of ARG1 deficiency. 3) Perturbations of NO metabolism merit future attention in ARG1 deficiency.
BACKGROUND:Arginase 1(ARG1) deficiency is a rare urea cycle disorder (UCD). This hypothesis-generating study explored clinical phenotypes, metabolic profiles, molecular genetics, and treatment approaches in a cohort of children and adults with ARG1 deficiency to add to our understanding of the underlying pathophysiology. METHODS: Clinical data were retrieved retrospectively from physicians using a questionnaire survey. Plasma aminoacids, guanidinoacetate (GAA), parameters indicating oxidative stress and nitric oxide (NO) synthesis as well as asymmetric dimethylarginine (ADMA) were measured at a single study site. RESULTS: Nineteen individuals with ARG1 deficiency and 19 matched controls were included in the study. In patients, paraparesis, cognitive impairment, and seizures were significantly associated suggesting a shared underlying pathophysiology. In patients plasma GAA exceeded normal ranges and plasma ADMA was significantly elevated. Compared to controls, nitrate was significantly higher, and the nitrite:nitrate ratio significantly lower in subjects with ARG1 deficiency suggesting an advantage for NO synthesis by inducible NO synthase (iNOS) over endothelial NOS (eNOS). Logistic regression revealed no significant impact of any of the biochemical parameters (including arginine, nitrates, ADMA, GAA, oxidative stress) or protein restriction on long-term outcome. CONCLUSION: Three main hypotheses which must be evaluated in a hypothesis driven confirmatory study are delineated from this study: 1) clinical manifestations in ARG1 deficiency are not correlated with arginine, protein intake, ADMA, nitrates or oxidative stress. 2) GAA is elevated and may be a marker or an active part of the pathophysiology of ARG1 deficiency. 3) Perturbations of NO metabolism merit future attention in ARG1 deficiency.
Authors: Joshua L Deignan; Peter P De Deyn; Stephen D Cederbaum; Arno Fuchshuber; Bernhard Roth; Wieland Gsell; Bart Marescau Journal: Mol Genet Metab Date: 2010-01-29 Impact factor: 4.797
Authors: Friedrich Schulze; Henrike Lenzen; Christoph Hanefeld; Asja Bartling; Karl J Osterziel; Lilia Goudeva; Caroline Schmidt-Lucke; Magda Kusus; Renke Maas; Edzard Schwedhelm; Dietrich Strödter; Bernd C Simon; Andreas Mügge; Werner G Daniel; Harald Tillmanns; Bernhard Maisch; Thomas Streichert; Rainer H Böger Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: S Scholl-Bürgi; S Baumgartner Sigl; J Häberle; E Haberlandt; K Rostásy; C Ertl; U Eichinger-Öttl; P Heinz-Erian; D Karall Journal: J Inherit Metab Dis Date: 2008-12-06 Impact factor: 4.982
Authors: Corinne M Rüegger; Martin Lindner; Diana Ballhausen; Matthias R Baumgartner; Skadi Beblo; Anibh Das; Matthias Gautschi; Esther M Glahn; Sarah C Grünert; Julia Hennermann; Michel Hochuli; Martina Huemer; Daniela Karall; Stefan Kölker; Robin H Lachmann; Amelie Lotz-Havla; Dorothea Möslinger; Jean-Marc Nuoffer; Barbara Plecko; Frank Rutsch; René Santer; Ute Spiekerkoetter; Christian Staufner; Tamar Stricker; Frits A Wijburg; Monique Williams; Peter Burgard; Johannes Häberle Journal: J Inherit Metab Dis Date: 2013-06-19 Impact factor: 4.982
Authors: Aseel Bin Sawad; Arti Pothukuchy; Mark Badeaux; Victoria Hodson; Gillian Bubb; Kristina Lindsley; Jennifer Uyei; George A Diaz Journal: JIMD Rep Date: 2022-03-25
Authors: George A Diaz; Andreas Schulze; Markey C McNutt; Elisa Leão-Teles; J Lawrence Merritt; Gregory M Enns; Spyros Batzios; Allison Bannick; Roberto T Zori; Leslie S Sloan; Susan L Potts; Gillian Bubb; Anthony G Quinn Journal: J Inherit Metab Dis Date: 2021-01-26 Impact factor: 4.982
Authors: Paula J Martinez; Marta Agudiez; Dolores Molero; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Aranzazu Santiago-Hernandez; Juan Manuel García-Segura; Felipe Madruga; Martha Cabrera; Eva Calvo; Gema Ruiz-Hurtado; Maria G Barderas; Fernando Vivanco; Luis M Ruilope; Gloria Alvarez-Llamas Journal: J Mol Med (Berl) Date: 2020-09-11 Impact factor: 4.599